Innovative antiviral drug

  • First innovative Russian direct-action drug for treating influenza
  • Based on a new small molecule (codename Camphecin)
  • Mechanism of action: inhibition of viral hemagglutinin
  • Patent protection: Russian patent
  • Indications for use: treatment of influenza and acute respiratory infections
  • • Main advantages:
    • high efficacy in models of influenza, induced by epidemically relevant viral strains (as effective as tamiflu);
    • satisfactory safety profile
  • Project stage: preclinical trials weree finished in 2019. Obtaining clinical trial permission is planned in 2020.